SPOTLIGHT: Sanofi says no charges on Plavix


Sanofi-Aventis says it isn't likely to face charges related to Plavix after Bristol-Myers Squibb pleaded guilty to misleading authorities about a failed deal to prevent a generic version of the drug from reaching the market. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.